Insulet Corporation with ticker code (PODD) have now 18 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $270.00 and $208.00 and has a mean target at $236.83. Now with the previous closing price of $166.25 and the analysts are correct then there would likely be a percentage uptick in value of 42.5%. The 50 day moving average now sits at $173.86 and the 200 moving average now moves to $190.80. The company has a market cap of 11.51B. The stock price for the company is currently $164.42 USD
The potential market cap would be $16,400,884,548 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 55.93, revenue per share of $24.33 and a 6.09% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
